Omeros' Q4 2025 earnings call highlighted a $240 million upfront asset sale and license deal with Novo Nordisk for zaltenibart, plus FDA approval of narsoplimab (YARTEMLEA) for transplant‑associated thrombotic microangiopathy, marking a turning point.
Comments